Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
Open Access
- 12 February 2015
- journal article
- research article
- Published by Wiley in Pediatric Diabetes
- Vol. 16 (3) , 164-176
Abstract
Insulin degludec (IDeg) once-daily was compared with insulin detemir (IDet) once- or twice-daily, with prandial insulin aspart in a treat-to-target, randomized controlled trial in children 1-17 yr with type 1 diabetes, for 26 wk (n = 350), followed by a 26-wk extension (n = 280). Participants were randomized to receive either IDeg once daily at the same time each day or IDet given once or twice daily according to local labeling. Aspart was titrated according to a sliding scale or in accordance with an insulin:carbohydrate ratio and a plasma glucose correction factor. Randomization was age-stratified: 85 subjects 1-5 yr. (IDeg: 43), 138 6-11 yr (IDeg: 70) and 127 12-17 yr (IDeg: 61) were included. Baseline characteristics were generally similar between groups overall and within each stratification. Non-inferiority of IDeg vs. IDet was confirmed for HbA1c at 26 wk; estimated treatment difference (ETD) 0.15% [-0.03; 0.32]95% CI . At 52 wk, HbA1c was 7.9% (IDeg) vs. 7.8% (IDet), NS; change in mean FPG was -1.29 mmol/L (IDeg) vs. +1.10 mmol/L (IDet) (ETD -1.62 mmol/L [-2.84; -0.41]95% CI , p = 0.0090) and mean basal insulin dose was 0.38 U/kg (IDeg) vs. 0.55 U/kg (IDet). The majority of IDet treated patients (64%) required twice-daily administration to achieve glycemic targets. Hypoglycemia rates did not differ significantly between IDeg and IDet, but confirmed and severe hypoglycemia rates were numerically higher with IDeg (57.7 vs. 54.1 patient-years of exposure (PYE) [NS] and 0.51 vs. 0.33, PYE [NS], respectively) although nocturnal hypoglycemia rates were numerically lower (6.0 vs. 7.6 PYE, NS). Rates of hyperglycemia with ketosis were significantly lower for IDeg vs. IDet [0.7 vs. 1.1 PYE, treatment ratio 0.41 (0.22; 0.78)95% CI , p = 0.0066]. Both treatments were well tolerated with comparable rates of adverse events. IDeg achieved equivalent long-term glycemic control, as measured by HbA1c with a significant FPG reduction at a 30% lower basal insulin dose when compared with IDet. Rates of hypoglycemia did not differ significantly between the two treatment groups; however, hyperglycemia with ketosis was significantly reduced in those treated with IDeg.Keywords
Funding Information
- Novo Nordisk
This publication has 33 references indexed in Scilit:
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week ExtensionThe Journal of Clinical Endocrinology & Metabolism, 2013
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal InsulinPharmaceutical Research, 2012
- Assessment and management of hypoglycemia in children and adolescents with diabetesPediatric Diabetes, 2009
- Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 DiabetesDiabetes Care, 2009
- Refining basal insulin therapy: what have we learned in the age of analogues?Diabetes/Metabolism Research and Reviews, 2007
- Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetesCurrent Medical Research and Opinion, 2005
- Unique Challenges for Pediatric Patients With DiabetesDiabetes Spectrum, 2005
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005
- Neurocognitive Correlates of Type 1 Diabetes Mellitus in ChildhoodChild Neuropsychology, 2004
- Adverse Events and Their Association With Treatment Regimens in the Diabetes Control and Complications TrialDiabetes Care, 1995